New Findings from National institute of Respiratory Diseases Ismael Cosio Villegas in HIV/AIDS Provides New Insights (Valganciclovir Modulates the Tumor Necrosis Factor Axis Molecules Expression and Cd4+t-cell Subsets In Disseminated Kaposi...).

Předmět:	TUMOR necrosis factors RESPIRATORY diseases AIDS VALGANCICLOVIR HIV
Zdroj:	AIDS Weekly; 12/25/2023, p87-87, 1p
Abstrakt:	A recent study conducted by researchers at the National Institute of Respiratory Diseases Ismael Cosio Villegas in Mexico City explored the use of valganciclovir (VGC) as an add-on therapy for patients with disseminated Kaposi Sarcoma/human immunodeficiency virus (DKS/HIV). The study compared two treatment schedules: an experimental regime (ER) and a conventional treatment (CT). The results showed that the ER scheme increased the frequency of naive and central memory CD4+ T cells and induced a balanced distribution of activated CD4+ T-cell subsets. Additionally, the ER scheme modulated the tumor necrosis factor (TNF) receptors (TNFR1 and TNFR2) levels, suggesting a better regulation of the inflammatory status. This research provides insights into potential clinical benefits for DKS/HIV patients by avoiding an exacerbated inflammatory process. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu